Who are BEKINDA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trintellix, Palonosetron (Group P), Palonosetron only, Treatment 2 Ondansetron, Dexamethasone, Ondansetron, Aprepitant, Kytril inj.+Kytril tab..

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bekinda.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BEKINDA — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BEKINDA (BEKINDA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin 5-HT3 receptor antagonist. Area: Gastroenterology.

phase 2 Serotonin 5-HT3 receptor antagonist 5-HT3 receptor Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

BEKINDA (BEKINDA) — RedHill Biopharma Limited. Bekinda is a delayed-release tablet formulation of ondansetron, a serotonin 5-HT3 receptor antagonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BEKINDA TARGET	BEKINDA	RedHill Biopharma Limited	phase 2	Serotonin 5-HT3 receptor antagonist	5-HT3 receptor
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01
Palonosetron (Group P)	Palonosetron (Group P)	University of Malaya	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Palonosetron only	Palonosetron only	NYU Langone Health	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Treatment 2 Ondansetron	Treatment 2 Ondansetron	Hamad Medical Corporation	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Dexamethasone, Ondansetron, Aprepitant	Dexamethasone, Ondansetron, Aprepitant	Ottawa Hospital Research Institute	marketed	Antiemetic combination (corticosteroid + 5-HT3 antagonist + NK1 antagonist)	Glucocorticoid receptor, 5-HT3 receptor, NK1 receptor
Kytril inj.+Kytril tab.	Kytril inj.+Kytril tab.	LG Life Sciences	marketed	5-HT3 receptor antagonist	5-HT3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin 5-HT3 receptor antagonist class)

CCTU · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
RedHill Biopharma Limited · 1 drug in this class
The First Affiliated Hospital of Xinxiang Medical College · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BEKINDA — Competitive Intelligence Brief. https://druglandscape.com/ci/bekinda. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing